Group 1 - The core point of the news is that Haichuang Pharmaceutical has launched its self-developed Class I anti-cancer drug, Deuteroenzalutamide soft capsules, which are now available nationwide for patients with metastatic castration-resistant prostate cancer [1][2] - The drug is specifically designed for adult patients who have progressed after treatment with Abiraterone acetate and chemotherapy, and who have not previously received new androgen receptor inhibitors [1] - Prostate cancer is the second most common cancer among men globally, with 1.467 million new cases reported in 2022, and China saw 134,000 new cases in the same year, indicating a rising trend in incidence [1] Group 2 - Deuteroenzalutamide soft capsules are the first innovative drug approved in China for patients with metastatic castration-resistant prostate cancer, highlighting its clinical significance and urgent demand [1][2] - The company emphasizes its commitment to ensuring the quality and stable supply of the drug while accelerating the development of its rich pipeline of innovative therapies for global patients [2] - The drug reportedly shows superior safety compared to other endocrine therapies, significantly reducing the incidence of central nervous system adverse events and common complications in elderly patients [1]